Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

NCT00130702 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Myelogenous Leukemia, Acute

Interventions

DRUG: gefitinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]